The newer fluoroquinolones

Infectious Disease Clinics of North America

Volumn 18, Issue 3, 2004, Pages 691-716

  O'Donnell, Judith A ^a   Gelone, Steven P ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; ENOXACIN; ERYTHROMYCIN; FLEROXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN; TIMENTIN; TROVAFLOXACIN;

ABDOMINAL PAIN; ACHILLES TENDON RUPTURE; ANAEROBIC INFECTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACTERIAL PNEUMONIA; BRONCHOSPASM; CHILL; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CRYSTALLURIA; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPEPSIA; EDEMA; EPIGASTRIC PAIN; GASTROINTESTINAL DISEASE; GONORRHEA; HAEMOPHILUS INFLUENZAE; HEADACHE; HEMATURIA; HEPATITIS; HOSPITAL INFECTION; HUMAN; HYPOTENSION; INSOMNIA; INTERSTITIAL NEPHRITIS; JOINT EFFUSION; KIDNEY DISEASE; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LOBAR PNEUMONIA; MAXILLA SINUSITIS; MOOD DISORDER; MYRINGOTOMY; NAUSEA; NONHUMAN; OBSTRUCTIVE JAUNDICE; OTITIS MEDIA; PHOTOALLERGY; PHOTOSENSITIVITY; PHOTOTOXICITY; PRURITUS; PSYCHOSIS; PYELONEPHRITIS; QT PROLONGATION; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHINOSINUSITIS; SEIZURE; SERUM SICKNESS; SEXUALLY TRANSMITTED DISEASE; SINUSITIS; SKIN INFECTION; SKIN PIGMENTATION; SLEEP DISORDER; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TACHYCARDIA; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; TREMOR; UREMIA; URINARY TRACT INFECTION; URTICARIA; VAGINITIS; VASCULITIS; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS;

EID: 4143050282     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2004.04.011     Document Type: Review

References (107)

1. Lesher G.T., Froelich E.J., Gruett J.H., et al. 1, 8-naphthyridine derivatives: a new class of chemotherapy agents. J Med Pharm Chem. 5:1962;1063
2. Ronald A.R., Tutck M., Petersdorf R.G. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med. 275:1966;1081
3. O'Donnell J.A., Gelone S.P. Fluoroquinolones. Infect Dis Clin N Am. 14:2000;489-513
4. Gootz T.D., Brighty K.E. Chemistry and mechanism of action of quinolone antibacterials. Andriole V.T. The quinolones. 1998;43 Academic Press, San Diego
5. Lewis R.J., Tsai F.T.F., Wigley D.B. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays. 18:1996;661
6. Shen L.L., Chu D.T.W. Type II DNA topoisomerases as antibacterial targets. Curr Pharm Des. 2:1996;195
7. Moreau N.J., Robaux H., Baron L., Tabany X. Inhibitory effects of the quinolones on pro- and eukaryotic DNA topoisomerases I and II. Antimicrob Agents Chemother. 34:1990;1955
8. Walker R.C. The fluoroquinolones. Mayo Clin Proc. 74:1999;1030
9. Maxwell A. The molecular basis of quinolone action. J Antimicrob Chemother. 30:1992;409
10. Oram M., Fisher L.M. 4-quinolone resistance mutations in the DNA gyrase of E. coli clinical isolates identified by using PCR. Antimicrob Agents Chemother. 35:1991;387
11. Vila J., Ruiz J., Goni P., et al. Quinolone resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother. 39:1997;757
12. Fukuda H., Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 43:1999;410
13. Gootz T.D., Zaniewski R., Haskell S., et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 40:1996;2691
14. Kaatz G.W., Seo S.M. Mechanism of fluoroquinolone resistance in genetically-related strains of Staphylococcus aureus. Antimicrob Agents Chemother. 41:1997;2733
15. Muoz R., delaCampa A.G. parC subunit of DNA topoisomerase of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 40:1996;2252
16. Pan X.S., Ambler J., Mehtar S., et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 40:1996;2321
17. Takahashi H., Kikuchi T., Shoji S., et al. Characterization of gyrA, gyrB, grlA, and grl B mutations in fluoroquinolone resistant clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 41:1998;49
18. Anderson M.I., MacGowan A.P. Development of the quinolones. J Antimicrob Chemother. 51:(Suppl S1):2003;1-11
19. Chu D.T.W., Fernandes P.B. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 33:1989;131
20. Domagala J.M. Structure-activity and structure-side effect relationship of the quinolone antibacterials. J Antimicrob Chemother. 33:1994;685
21. Hawkey P.M. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother. 51:(Suppl S1):2003;29-35
22. Zhao X., Wang J.-Y., Xu C., Dong Y., Zhou J., Domagala H., et al. Killing of Staphylococcus aureus by C-8methoxy fluoroquinolones. Antimicrob Agents Chemother. 42:1998;956
23. Scheld W.M. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 9:2003;1-9
24. Wise R. Maximizing efficacy and reducing the emergence of resistance. J Antimicrob Chemother. 51:(Suppl S1):2003;37-42
25. Breines D.M., Quabdesselam S., Ng E.Y., Tankovic J., Shah S., Soussy C.J., et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother. 41:1997;175
26. Brenwald N.P., Gill M.J., Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 42:1998;2032
27. Finch R., et al. Randomized controlled trial of sequential intravenous and oral moxifloxacin compared with sequential IV and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 46:2002;1746-1754
28. Kohler T., Pechere J.-C. Bacterial resistance to quinolones: mechanisms and clinical implications. Andriole V.T. The quinolones. 2000;Academic Press, London
29. Chen F.J., Lo H.J. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect. 36:2003;1-9
30. Drlica K. Refining the fluoroquinolones. ASM News. 65:1999;410
31. Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther. 21:1999;3
32. Burkhardt J.E., Hill M.A., Carlton W.W., et al. Difloxacin reduces glycosaminoglycan synthesis in organ cultures of articular cartilage. Goldberg A.M. In vitro toxicology: mechanisms and new technology. 1991;371-377 Mary Ann Liebert, New York
33. Cohen S.P., Hooper T.D., Wolfson J.S., et al. Endogenous active efflux of norfloxacin in susceptible E. coli. Antimicrob Agents Chemother. 32:1988;1187
34. Kaatz G.W., Seo S.M., Ruble A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 37:1993;1086
35. Miyame S., Nidaido H., Tanaka T., et al. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob Agents Chemother. 42:1998;2119
36. Suh B., Lorber B., Gelone S., Truant A., et al. Development of high level quinolone resistance in Streptococcus pneumoniae during sequential quinolone therapy. Drugs. 58:(Suppl 2):1999;383
37. Yamada H., Kurose-Hamada S., Fukuda Y., et al. Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrob Agents Chemother. 41:1997;2308
38. Zeller V., Janoir C., Kitzi S.L., et al. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:1997;1973
39. Kim M.-K., Nightingale C.N. Pharmacokinetics and pharmacodynamics of the fluoroquinolones. Andriole V.T. The quinolones. 2000;Academic Press, London
40. Schentag J.J., Scully B.E. Quinolones. Yu V.L., Merigan T.C. Jr., Barriere S. Antimicrobial therapy and vaccines. 1999;875 Williams & Wilkins, Baltimore
41. Blaser J., Stone B.B., Groner M.C., Zinner S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 31:1987;1054
42. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a paradigm for early clinical trials. JAMA. 279:1998;125
43. Schentag J.J., Nix D.E., Adelman M.H. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Ann Pharmacother. 1991;1050-1052
44. Schentag J.J., Nix D.E., Forrest A., Adelman M.H. AUIC: the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother. 30:1997;1029
45. Dalhoff A., Schmitz F.-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 22:2003;203-221
46. Phillips I., King A., Shannon K. Comparative in vitro properties of the quinolones. Andriole V.T. The quinolones. 2000;Academic Press, London
47. Emmerson A.M., Jones A.M. The quinolones: decades of development and use. J Antimicrob Chemother. 51:(Suppl S1):2003;13-20
48. Liebetrau A., Rodloff A.C., Behra-Miellet J., Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother. 47:2003;3667-3671
49. Renau T.E., Gage J.W., Dever J.A., Roland G.E., Joannides E.T., Shapiro M.A., et al. Structure-activity relationships of quinolone agents against Mycobacteria: effect of structural modifications at the 8 position. Antimicrob Agents Chemother. 40:1996;2367
50. Tomioka H., Saito H., Sato K. Comparative antimycobacterial activities of the newly synthesized quinolones AM-1158, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother. 37:1993;1259
51. Hooton T.M., Stamm W.E. The vaginal flora and urinary tract infections. Mobley M.L.T., Warren J.W. Urinary tract infections. 1996;67 ASM Press, Washington
52. Fishman NO, Suh B, Weigel LM, et al. Three levofloxacin treatment failures of pneumococcal respiratory tract infections [abstract]. Presented at the 39th International Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 26-29, 1999.
53. Ross J.J., Worthington M.G., Gorbach S.L., Tillotson G.S., Zhao X., Drlica K., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 347:2002;65-67
54. Goldstein E.J.C. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, sparfloxacin DU-6859a) in the treatment of anaerobic infections: review of current information and efficacy. Clin Infect Dis. 23:(Suppl 1):1996;S25
55. Edelstien P.H. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med. 15:1998;328
56. Ball P. Adverse reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother. 51:(Suppl S1):2003;21-27
57. Christ W., Esch B. Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract. 3:(Suppl 3):1994;S168
58. Christ W., Lehnert T. Toxicity of the quinolones. Siporin C., Heifetz C.L., Domagala J.M. The new generation of quinolones. 1990;Marcel Decker, New York
59. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis. 28:1999;352
60. Schaad U.B. Use of the quinolones in pediatrics. Andriole V.T. The quinolones. 2000;Academic Press, London
61. Stahlmann R., Lode H. Safety overview: toxicity, adverse effects, and drug interactions. Andriole V.T. The quinolones. 2000;Academic Press, London
62. Brand H.S., van Kampen G.P.J., van der Korst J.K. Effect of nalidixic acid, pipemidic acid, and cinoxacin on chondrocyte metabolism in explants of articular cartilage. Clin Exp Rheumatol. 8:1990;393
63. Burkhardt J.E., Hill M.A., Carlton W.W. Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin. Toxicol Pathol. 20:1992;246
64. Chen D.K., McGeer A., deAzavedo J.C., et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 341:1999;233
65. Stahlmann R., Forster C., Shakibaei M., et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy. Antimicrob Agents Chemother. 39:1995;2013
66. Khaliq Y., Zhanel G.G. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 36:2003;1404-1410
67. Sharpnack D.D., Mastin J.P., Childress C.P., et al. Quinolone arthropathy in juvenile New Zealand white rabbits. Lab Anim. 44:1994;436
68. Hampel B., Hullman R., Schmidt K. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use safety report. Pediatr Infect Dis J. 16:1997;127
69. Bethell D.B., Hien T.T., Phi L.T., et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child. 74:1996;44
70. Church D.A., Kanga J.F., Kuhn R.J., et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study versus ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J. 16:1997;97
71. Rodvold K.A. Clinical safety profile of newer fluoroquinolones. Infect Med. 10:1999;41
72. Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of moxifloxacin [abstract P0208]. Presented at the 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany, 1999. p. 404.
73. Niki Y., Hashiguchi K., Okimoto N., et al. Quinolone antimicrobial agents and theophylline. Chest. 101:1992;881
74. Davis R., Bryson H.M. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 47:1994;677
75. Dunbar L.M., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 37:2003;752-760
76. West M., et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 25:2003;485-506
77. Graham D.R., et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin/clavulanate for complicated skin and skin structure infections: a randomized, open-trial. Clin Infect Dis. 35:2002;381-389
78. Tarshis G.A., et al. Once-daily oral gatifloxacin versus oral levofloxacin in the treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 45:2001;2358-2362
79. Sher L.D., Poole M.D., Von Seggern K., Wikler M.A., Nicholson S.C., Pankey G.A. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. Otolaryngol Head Neck Surg. 127:2002;182-189
80. Sher L.D., McAdoo M.A., Bettis R.B., Turner M.A., Li N.F., Peirce P.F. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. Clin Ther. 24:2002;269-281
81. Soler M., et al. Randomised, double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic bronchitis. Eur J Clin Microbiol Infect Dis. 22:2003;144-150
82. Nicholson S.C., Webb C.D., Andriole V.T., Jones R.N., Wilson W.R. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. Diagn Microbiol Infect Dis. 44:2002;101-107
83. Correa J.C., et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther. 25:2003;1453-1468
84. Jones R.N., Andes D.R., Mandell L.A., Gothelf S., Ehrhardt A.F., Nicholson S.C. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 44:2002;93-100
85. Nicholson S.C., Wilson W.R., Naughton B.J., Gothelf S., Webb C.D. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Diagn Microbiol Infect Dis. 44:2002;117-125
86. Leibovitz E., et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J. 22:2003;943-949
87. Arguedas A., et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J. 22:2003;949-956
88. Richard G.A., Mathew C.P., Kirstein J.M., Orchard D., Yang J.Y. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 59:2002;334-339
89. Cox C.E., et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther. 24:2002;223-236
90. Stoner B.P., et al. Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial. Sex Transm Dis. 28:2001;136-142
91. Parish L.C., et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract. 54:2000;497-503
92. Klossek J.M., et al. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. J Laryngol Otol. 117:2003;43-51
93. Siegert R., et al. A comparison of the safety and efficacy of moxifloxacin and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med. 94:2000;337-344
94. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., Church D. Short-course moxifloxacin therapy for the treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchits Study Group. Respir Med. 94:2000;18-27
95. Grassi C., et al. Efficacy and safety of short course (5-day) moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 14:2002;597-608
96. Schaberg T., et al. A multinational, multicenter, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res. 29:2001;314-328
97. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., Church D. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med. 94:2000;1029-1037
98. Lode H., et al. Sequential IV/po moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med. 97:2003;1134-1142
99. Hoeffken G., Meyer H.P., Winter J., Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community acquired pneumonia. Respir Med. 95:2001;553-564
100. Petitpretz P., Arvis P., Marel M., Moita J., Urueta J. Oral moxifloxacin versus high-dosage amoxicillin in the treatment of mild-to-moderate community-acquired, suspected pneumococcal pneumonia in adults. Chest. 119:2001;185-195
101. Ferguson B.J., et al. Short treatment durations for acute bacterial rhinosinusitis: five days of gemifloxacin versus 7 days of gemifloxacin. Otolaryngol Head Neck Surg. 127:2002;1-6
102. Wilson R., Langan C., Ball P., Bateman K., Pypstra R. Oral gemifloxacin once daily with IV ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med. 97:2003;242-249
103. Wilson R., Schentag J.J., Ball P., Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 24:2002;639-652
104. File T., Schlemmer B., Garau J., Lode H., Lynch S., Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 clinical study group. J Chemother. 12:2000;314-325
105. Ball P., Wilson R., Mandell L., Brown J., Henkel T. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J Chemother. 13:2001;288-298
106. Lode H., et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther. 24:2002;1915-1936
107. File T.M. Jr., Schlemmer B., Garau J., Cupo M., Young C. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother. 48:2001;67-74